세계의 맥락막 신생혈관 시장 : 제품 유형별, 치료 유형별, 질환 유형별, 최종 사용자별 - 예측(2025-2030년)

The Choroidal Neovascularization Market was valued at USD 5.95 billion in 2023, expected to reach USD 6.38 billion in 2024, and is projected to grow at a CAGR of 7.57%, to USD 9.93 billion by 2030.

Choroidal Neovascularization (CNV) involves the formation of new blood vessels in the choroid layer of the eye, often linked to severe vision impairment and conditions like age-related macular degeneration (AMD). The market for CNV treatment is driven by the necessity for innovative therapeutic approaches due to the rising prevalence of AMD among aging populations globally. Current applications include anti-VEGF (vascular endothelial growth factor) therapies, laser treatment, and photodynamic therapy, with end-users spanning ophthalmology clinics, hospitals, and specialized eye care centers. Market growth is influenced by advancements in drug delivery systems, increasing patient awareness, and ongoing research focused on improving treatment efficacy. Moreover, technological innovations, particularly in biologics and gene therapy, present significant opportunities for companies to expand their product portfolios. However, challenges such as the high cost of treatments, regulatory hurdles, and potential side effects necessitate continuous research and innovation to ensure more effective and affordable solutions.

Key opportunities lie in the development of sustained-release drug formulations and personalized medicine, leveraging genetic markers for individualized treatment plans. Companies could invest in collaborative research efforts to explore novel mechanisms of action and combination therapies that could enhance patient outcomes. Despite these opportunities, the market faces limitations such as treatment resistance and the complexity of CNV pathophysiology, which complicates the development of universal treatments. Additionally, economic factors and healthcare accessibility issues pose challenges to market penetration, particularly in low-income regions. Areas of innovation with high potential include AI-assisted diagnostics to optimize treatment protocols, and nanotechnology-enhanced drug delivery systems designed to target CNV tissues precisely and reduce collateral damage to surrounding eye structures. For business growth, focusing on partnerships with research institutions and actively participating in global clinical trials can provide valuable insights into emerging trends and technologies, helping firms remain competitive in a dynamic and evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Choroidal Neovascularization Market

The Choroidal Neovascularization Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of age-related macular degeneration (AMD) and related disorders in aging population
  • Enhanced awareness about early diagnosis and treatment
• Market Restraints
  • High cost of treatment limiting the accessibility
• Market Opportunities
  • Leveraging artificial intelligence for early diagnosis using retinal imaging
  • Developing sustained-release implants and injections for reducing the frequency of treatments
• Market Challenges
  • Potential side effects and complications associated with current treatments

Porter's Five Forces: A Strategic Tool for Navigating the Choroidal Neovascularization Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Choroidal Neovascularization Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Choroidal Neovascularization Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Choroidal Neovascularization Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Choroidal Neovascularization Market

A detailed market share analysis in the Choroidal Neovascularization Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Choroidal Neovascularization Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Choroidal Neovascularization Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Choroidal Neovascularization Market

A strategic analysis of the Choroidal Neovascularization Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Choroidal Neovascularization Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Bausch + Lomb Corporation, Bausch Health, Bayer AG, Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Clearside Biomedical, F. Hoffmann-La Roche Ltd., Genentech USA, Inc., Genentech, Inc., Iveric Bio, Kodiak Sciences, Kodiax Pharmaceuticals, Novartis AG, PulseSight Therapeutics, Regeneron Pharmaceuticals Inc., Samsung Bioepis., Sandoz Inc., and Santen Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Choroidal Neovascularization Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Biologics, Devices, and Drugs.
• Based on Treatment Type, market is studied across Anti-VEGF Drugs, Laser Photocoagulation, and Photodynamic Therapy.
• Based on Disease Type, market is studied across Type 1, Type 2, and Type 3.
• Based on End-User, market is studied across Hospitals, Ophthalmology Clinics, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of age-related macular degeneration (AMD) and related disorders in aging population
    • 5.1.1.2. Enhanced awareness about early diagnosis and treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment limiting the accessibility
  • 5.1.3. Opportunities
    • 5.1.3.1. Leveraging artificial intelligence for early diagnosis using retinal imaging
    • 5.1.3.2. Developing sustained-release implants and injections for reducing the frequency of treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Potential side effects and complications associated with current treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product type: Increasing preference for biologics due to their targeted mechanism of action and efficacy.
  • 5.2.2. End-user: Increasing need in hospitals due to presence of a wide range of treatment options, including laser therapy, anti-VEGF injections, and photodynamic therapy.
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Choroidal Neovascularization Market, by Product Type

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Devices
• 6.4. Drugs

7. Choroidal Neovascularization Market, by Treatment Type

• 7.1. Introduction
• 7.2. Anti-VEGF Drugs
• 7.3. Laser Photocoagulation
• 7.4. Photodynamic Therapy

8. Choroidal Neovascularization Market, by Disease Type

• 8.1. Introduction
• 8.2. Type 1
• 8.3. Type 2
• 8.4. Type 3

9. Choroidal Neovascularization Market, by End-User

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Ophthalmology Clinics
• 9.4. Research Institutes

10. Americas Choroidal Neovascularization Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Choroidal Neovascularization Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Choroidal Neovascularization Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Biocon Biologics receives FDA approval for Yesafili, an ophthalmology biosimilar interchangeable with aflibercept, targeting market growth
  • 13.3.2. Santen Pharmaceutical and Bayer Yakuhin launched Eylea 8mg in Japan to improve nAMD and DME treatment with higher concentration formula
  • 13.3.3. Sandoz USD 170 million acquisition of biosimilar ranibizumab CIMERLI from Coherus BioSciences bolsters ophthalmology market presence and portfolio
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adverum Biotechnologies
• 2. Apellis Pharmaceuticals, Inc.
• 3. Astellas Pharma Inc.
• 4. Bausch + Lomb Corporation
• 5. Bausch Health
• 6. Bayer AG
• 7. Biogen, Inc.
• 8. Chugai Pharmaceutical Co., Ltd.
• 9. Clearside Biomedical
• 10. F. Hoffmann-La Roche Ltd.
• 11. Genentech USA, Inc.
• 12. Genentech, Inc.
• 13. Iveric Bio
• 14. Kodiak Sciences
• 15. Kodiax Pharmaceuticals
• 16. Novartis AG
• 17. PulseSight Therapeutics
• 18. Regeneron Pharmaceuticals Inc.
• 19. Samsung Bioepis.
• 20. Sandoz Inc.
• 21. Santen Pharmaceutical Co. Ltd.